stockmarketnews.online EDGAR snapshot
The Filings Docket Corporate filings, explained: what large U.S. companies filed with the SEC, and what it means.

In re: VERTEX PHARMACEUTICALS INC / MA · CIK 0000875320

When will Vertex Pharmaceuticals Inc. file its next 10-Q?

VRTX · Nasdaq
Snapshot

Vertex Pharmaceuticals Inc. is expected to file its next quarterly report (Form 10-Q), for the period ending about Sept. 30, 2026, between Nov. 2, 2026 and Nov. 6, 2026, based on its last 8 10-Q filings. The SEC deadline for a large accelerated filer is Nov. 9, 2026.

How the next-report window is calculated

Vertex Pharmaceuticals Inc.'s most recent periodic report on file is a Form 10-Q for the period ended June 30, 2026, filed Aug. 4, 2026. Its fiscal year ends around Dec. 31, so the next period should close about Sept. 30, 2026, and that report is a Form 10-Q.

SEC rules give a large accelerated filer 40 days after period end to file a 10-Q, which lands on Nov. 9, 2026 after moving off weekends and federal holidays. Over its last 8 10-Qs, Vertex Pharmaceuticals Inc. filed between 33 and 37 days after period end (median 36 days), which gives the expected window above. Period ends are estimated from the company's own calendar and may shift by a few days in 52/53-week fiscal years.

Vertex Pharmaceuticals Inc.: days from period end to 10-Q/10-K filing 10-Q for period ended 2024-09-30: filed 36 days later; 10-K for period ended 2024-12-31: filed 44 days later; 10-Q for period ended 2025-03-31: filed 36 days later; 10-Q for period ended 2025-06-30: filed 36 days later; 10-Q for period ended 2025-09-30: filed 35 days later; 10-K for period ended 2025-12-31: filed 44 days later; 10-Q for period ended 2026-03-31: filed 35 days later; 10-Q for period ended 2026-06-30: filed 35 days later. 10-Q due: 40d 10-K due: 60d 10-Q · Sept. 30 24 36d 10-K · Dec. 31 24 44d 10-Q · March 31 25 36d 10-Q · June 30 25 36d 10-Q · Sept. 30 25 35d 10-K · Dec. 31 25 44d 10-Q · March 31 26 35d 10-Q · June 30 26 35d days from period end to filing date →

Recent filings by Vertex Pharmaceuticals Inc.

Most recent 25 filings excluding insider Forms 3/4/5/144 · SEC EDGAR, retrieved Oct. 16, 2026
FiledFormWhat it isDocument
8-K Executive or board change, or executive pay arrangement Open 8-K filed 2026-09-01 · Index 0000875320-26-000264
10-Q Quarterly report with unaudited financial statements for the period ended June 30, 2026 Open 10-Q filed 2026-08-04 · Index 0000875320-26-000259
8-K Released earnings or financial results Open 8-K filed 2026-08-03 · Index 0000875320-26-000256
8-K Signed a material contract; information shared under Regulation FD; other events the company chose to report Open 8-K filed 2026-07-07 · Index 0001193125-26-296710
13G/A Amendment to a passive-ownership (13G) report Open SCHEDULE 13G/A filed 2026-05-14 · Index 0001422849-26-000080
13G/A Amendment to a passive-ownership (13G) report Open SCHEDULE 13G/A filed 2026-05-14 · Index 0001422848-26-000067
S-8 Registration of shares for employee benefit plans Open S-8 filed 2026-05-13 · Index 0000875320-26-000206
8-K Executive or board change, or executive pay arrangement; reported shareholder vote results Open 8-K filed 2026-05-13 · Index 0000875320-26-000204
10-Q Quarterly report with unaudited financial statements for the period ended March 31, 2026 Open 10-Q filed 2026-05-05 · Index 0000875320-26-000173
8-K Released earnings or financial results Open 8-K filed 2026-05-04 · Index 0000875320-26-000171
13G Ownership above 5% by a passive or institutional investor Open SCHEDULE 13G filed 2026-04-30 · Index 0002100119-26-001217
DEFA14A Additional proxy soliciting materials Open DEFA14A filed 2026-04-29 · Index 0000875320-26-000167
8-K Executive or board change, or executive pay arrangement Open 8-K filed 2026-04-29 · Index 0000875320-26-000166
ARS Annual report delivered to shareholders Open ARS filed 2026-04-02 · Index 0000875320-26-000155
DEFA14A Additional proxy soliciting materials Open DEFA14A filed 2026-04-02 · Index 0000875320-26-000154
DEF 14A Definitive proxy statement for a shareholder meeting Open DEF 14A filed 2026-04-02 · Index 0000875320-26-000153
8-K Other events the company chose to report Open 8-K filed 2026-03-31 · Index 0000875320-26-000147
13G/A Amendment to a passive-ownership (13G) report Open SCHEDULE 13G/A filed 2026-03-27 · Index 0000102909-26-002578
10-K Annual report with audited financial statements for the period ended Dec. 31, 2025 Open 10-K filed 2026-02-13 · Index 0000875320-26-000056
8-K Released earnings or financial results Open 8-K filed 2026-02-12 · Index 0000875320-26-000034
13G/A Amendment to a passive-ownership (13G) report Open SCHEDULE 13G/A filed 2026-02-12 · Index 0001422848-26-000023
10-Q Quarterly report with unaudited financial statements for the period ended Sept. 30, 2025 Open 10-Q filed 2025-11-04 · Index 0000875320-25-000232
8-K Released earnings or financial results Open 8-K filed 2025-11-03 · Index 0000875320-25-000230
10-Q Quarterly report with unaudited financial statements for the period ended June 30, 2025 Open 10-Q filed 2025-08-05 · Index 0000875320-25-000216
10-Q Quarterly report with unaudited financial statements for the period ended March 31, 2025 Open 10-Q filed 2025-05-06 · Index 0000875320-25-000192

What Vertex Pharmaceuticals Inc.'s 8-Ks were about in the past year

Vertex Pharmaceuticals Inc. filed 9 Form 8-K current reports between Oct. 17, 2025 and Oct. 16, 2026. Each report lists the item numbers it covers; the counts below show how often each item appeared.

ItemMeaningTimes
9.01Financial Statements and Exhibits5
2.02Results of Operations and Financial Condition4
5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers3
8.01Other Events2
1.01Entry into a Material Definitive Agreement1
7.01Regulation FD Disclosure1
5.07Submission of Matters to a Vote of Security Holders1

See what each 8-K item means.